الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 67 |  |  |
| | | from | 67 | | |
Abstract
Bovine Colostrum is a rich source of nutrients and biologically active molecules that are essential for several specific functions including defensive action, the modulation of immune response, the balancing of intestinal microbiota and the growth and repair of several tissues. The components of colostrum can intervene in various pathogenesis phases of several diseases, thus contributing to an improvement of clinical symptoms. Colostrum may also have a preventive action or reduce the side effects of several drugs that are currently used for treating various diseases.
The previous studies showed that bovine colostrum have a good role in the treatment of acute diarrhea in children. The aim of this work was to study the role of bovine colostrum in the treatment of acute diarrhea in children. The study was conducted on 160 infants attending Alexandria University Children’s Hospital with acute diarrhea in a period from November 2016 to April 2017 with exclusion of children with history of diarrhea more than 48 hours, children who received Prior treatment with antibiotics or anti diarrheal and children with history of malnutrition and chronic diseases. Ages of the studied infants ranged from 6 months to 2 years with a mean of 12.303 ± 4.149 months. 78 patients (48.8%) were males and 82 patients (51.25%) were females.
The children were classified into two groups: First Group: included 80 patients who were treated with standard therapy of acute diarrhea plus bovine colostrum. The second Group: included 80 patients who received standard therapy of acute diarrhea plus placebo. The two groups were matched before treatment in basic descriptive data, Vesikari scoring and initial clinical presentation.
The result of the study showed the following:
The frequency of diarrhea in the BC group was significantly lower when compared with the placebo group after 48 hours follow up and 1 week follow up.
Duration of diarrhea in the BC group was significantly shorter when compared with placebo group The frequency of vomiting in the BC group was significantly lower when compared with placebo group at 48 hours follow up.
Disappearance of vomiting and fever in the BC group were significantly earlier when compared with placebo group.
Vesikari scoring in the BC group was significantly lower when compared with placebo group at 48 hours follow up and 1 week follow up.
The Vesikari scoring was significantly lower at 48hours follow up and 1 week follow up when in Rota positive patients who received BC compared with Rota positive patients who received placebo.
The Vesikari scoring was significantly lower at 48hours and 1 week follow up in E coli positive patients who received BC when compared with E.coli positive patients received placebo. Also disappearance of diarrhea in E.coli positive patients received BC was significantly earlier when compared with positive E. coli patients receiving placebo.
CRP was statistically significant predictor for E.coli positive probability.
Frequency of vomiting was statistically significant predictor for E.coli positive probability.
High grade of fever was statistically significant predictor for E.coli positive probability.
In conclusion, BC is effective in the treatment of acute diarrhea so BC could be used as adjuvant therapy for acute diarrhea in children. Further multicentered studies are needed to confirm the role of BC in acute diarrhea.